Search 

Guoqian Venture Capital is one of the two business platforms; the other is Guoqian Medical Technology Innovation Research Institute, which is an incubator/accelerator for startup and growth companies.
Guoqian Venture Capital is a professional and market-oriented venture capital firm that focuses on equity investment in early innovation and entrepreneurship projects in the fields of medical devices, in vitro diagnostic reagents and biotechnology. Focusing on innovative technologies and products. Due to currency restrictions, the firm can only invest in entities in China. The investment size is from ￥5 million （$750k) to ￥20 million ($ 3 million).
Guoqian Medical Technology Innovation Research Institute is committed to cultivating cutting-edge technologies and projects in Chinese medical device industry, and providing it with multi-faceted technologies, policies, talents, industrialization and markets through direct investment, entrepreneurial services, and scientific and technological achievement transformation services. Integration of services and resources to create an innovative platform for national technological innovation and industrial integration and empowerment. At the same time, it has also become an enabling platform for post-investment enterprises of Guoqian Fund. By creating industrial clusters and industrial ecology, it will provide post-investment management, post-investment services, and post-investment empowerment to post-investment enterprises.
Based on the business philosophy of “achieving the dreams of others”, Guoqian Medical uses market-oriented and specialized equity investment funds to create industrial agglomeration and industrial ecology; it empowers post-investment enterprises by creating industrial agglomeration and industrial ecology. The two platforms complement each other, and strive to build a medical device industry cluster and ecosystem in Suzhou High-tech Zone in 10 years, becoming one of the main promoters of the domestic medical device industry.

HebeCell was founded in 2016 by industry leading inventors in developing the manufacturing platform of hematopoietic cells from human pluripotent stem cells (PSCs). Their first-in-class proprietary 3D manufacturing platform for human iPS-NK cells is feeder-free, designed specifically for single-use-bioreactor at industrial scale. HebeCell’s platform will accelerate the application of PSCs as a viable source of immune cells in the next generation of immune cell therapies for immune-Oncology, autoimmune and infectious diseases.

Dr. John Lu is the President and CEO of HebeCell. Before establishing HebeCell, John was the Senior Director of Research at Advanced Cell Technology/Ocata Therapeutics, which in 2016 was acquired by Astellas, the second-largest pharmaceutical company in Japan. John is an expert in stem cell biology and regenerative medicine with 20 years of experience in the field.

Dr. Allen Feng is the Chief Scientific Officer of the HebeCell Corp. Prior to establishing HebeCell, he was the Director of Cell Biology of Semma Therapeutics, which was acquired by Vertex Pharmaceuticals in 2019. Prior to Semma, Allen worked as R&D Head of Stem Cell Bioprocessing Group at EMD Millipore, and also served as Director and Senior Scientist at Advanced Cell Technology /Ocata Therapeutics.

Incuron is a private clinical-stage company that develops a novel class of synthetic small molecules, Curaxins, with a unique multi-targeted mechanism of antitumor activity. These chromatin damaging agents interfere with histone/DNA binding causing decondensation of chromatin in tumor cells, functional inactivation of histone chaperone FACT, and simultaneous effect on a set of universal previously undruggable targets, leading to inhibition of pro-cancer transcriptional factors, MYC, NF-kB, HIF1a, and HSF-1, and activation of the tumor suppressor p53, as well as induction of type I interferon response.
Key advantages of curaxins based on current preclinical and early clinical data include:
- novel mechanism of action that would bring the additional treatment option for advanced and relapsed tumors, as well as potential to overcome resistance to previous treatments;
- favorable pharmacology and manageable safety profiles;
- low potential for serious drug-drug interactions providing opportunities for combinatorial therapeutic regimens;
- broad activity in different tumor types that may open wider market opportunities;
- focused phase 2 clinical study program can establish faster clinical proof of concept and build toward accelerated regulatory approval.
Incuron owns a worldwide patent portfolio, including the composition of matter and therapeutic uses of the compounds.

InvivoSciences, Inc. (IVS) is a preclinical stage biotech company with a team of drug development experts, including Dr. Joseph Schlessinger, who developed various therapies including, a blockbuster drug - Sutent.
With an increasingly aging population with chronic diseases such as diabetes, heart failure is an urgent and critical challenge without an effective solution. There have been no successful phase III trials in worsening chronic heart failure or heart failure with preserved ejection fraction (HFpEF). Large clinical trials required for the heart failure trials have been the bottleneck. There is clear evidence showing that genetic factors drive heart failure development. Our mission is to cure heart failure one gene at a time.
We have leveraged our advanced artificial intelligence integrated breakthrough in precision medicine discovery platform using patient-derived human micro heart on a chip, NuHeart™, to identify and validate multiple drug pipelines rapidly as well as help us to determine biomarkers and stratify the patients for a clinical trial recruitments. Our precision heart failure pipelines are at least ten times more cost-effective to develop, especially during their clinical stages. Using our platform, we have developed two pipelines of small-molecule candidates for difficult to treat, genetically defined heart failure conditions. Our Pipelines of precision medicines have the potential to deliver better outcomes for patients fighting hard to treat heritable heart disease.
Collaborative patient-driven precision medicine-based drug development empowered with our novel platform will lead to meaningfully better outcomes for heart failure patients, which we refer to as InvivoSciences’ discovery engine to develop target therapies. Our lead program includes candidates in preclinical development for monogenetic heart failures. To date, IVS raised $8.5 Million non-dilutive funding from founders, board, commercial contracts, and grants. The funds have been used to create a portfolio of assets (breakthrough discovery platform, NuHeart™, three genetically defined disease models, current discovery programs, and a strong portfolio of patents including both US and international.
To join and support our drug discovery programs forward, InvivoSciences is seeking world-class life science investors and strategic partners for our Series A round for growth capital for $10 M in two trunches for commercial growth and accelerating our drug program.

We are a pharmaceutical startup in Memphis, Tennessee. Our focus is on pediatric drug delivery designs as we transform FDA approved therapeutic compounds into pediatric friendly drug delivery systems. We have designed several Epinephrine prodrugs to eliminate the need to use Epipen injections. We seek seed funding for organic synthesis, formulation development and CMC drug development.

JOT is a virtual company with its base operation in Jupiter, FL. JOT is in position to quickly come to market with a platform product effective to treat 12 or more indications including Alzheimer’s Disease. The proprietary patented product, JOTROL, is very safe, oral, naturally based and multi-functional. JOTROL will be very effective with high social and economic impact within a reasonable timeframe. Relationships have been developed with scientists at various institutions, such as University of Miami (“UM”), MIT, Harvard, Georgetown University and Murdoch Childrens Research Institute, AU. This setup has made it possible to gain access to laboratory work, scientific information, pre-clinical development and scientific expertise in an extremely cost effective and efficient way. JOT will conclude clinical trials by utilizing a contract manufacturer and Clinical Research Organizations, involvement by its scientific advisors as well as support from patient organizations thereby keeping its fixed overhead extremely low for a Biotech company. A Phase I trial is presently ongoing with results expected in Q1,2021. Two Phase II rare disease trials, are expected to be started in H2 of 2021 with possible accelerated approvals from FDA. Partial financing for those are expected to be received from NIH. A Phase II trial in Alzheimer’s is also planned to be executed in parallel. Financing for the Phase I study has been granted by NIA (National Institute of Aging). Financing for a larger Phase II study is also expected to be financed by a NIA consortium (up to $75 million). JOT is prepared to add a commercial organization to market its product in North America while out-licensing marketing and sales operations for the rest of the world.

Company:
Maculus Therapeutix is a preclinical-stage biopharmaceutical company focused on finding practical solutions to treat chronic diseases of the retina and optic nerve such as wetAMD (Age related Macular Degeneration) in the Ophthalmology space with a novel tunable biodegradable proprietary product – MacuBloc™ capable of delivering any FDA approved drugs for Wet AMD to the site of the disease. With its unique suitability for targeted and extended delivery of drugs to back of the human eyes, MacuBloc™ offers significant benefits to Wet AMD patients over existing products: a single intravitreal injection that lasts an year instead of the current 10-12 monthly injections plus significant potential reduction in inflammation, infection, doctor visits and total cost of care compared to current practice.

Market:
The global market size of Age-Related Macular Degeneration (AMD) is currently $7.7B, growing at 7.6% CAGR and is expected to reach a value of $11B by 2025. Current standard of care involves 10-12 monthly injections with a 30 gauge syringe needle going through the eye sclera, often resulting post-injection pain and possible infection due to repeated injections in a small area as well as ruptured blood vessels in the sclera. By reducing the number of injections from 10+ to just ONE, MacuBloc™ formulation is likely to be a treatment of choice.

MEDGENE is a T cell therapy biotech start-up (late pre-clinical stage) based in Maryland, USA.

- Focused on developing PD1+ peripheral blood-derived, tumor-reactive CD8+ T cell (PBTL) therapies as a platform for the treatment of solid tumors that are rare, orphan, and have critical (high) unmet need
- PBTL is a simpler, smarter version of TIL 
- PBTL is a process to select highly tumor-reactive T cells from a patient's peripheral blood based on the expression of two specific T cell surface markers: PD-1 and/or TIM-3 

- After selection, expanded to large quantities, it gets re-infused into the patient via the ACT regimen

- PBTL technology has been patented (issued) already in the US, China, the EU, Japan, Australia 
- MEDGENE has robust Clinical Development Pipelines (currently, 9 as monotherapy way)

- Looking for funding for entering Phase 1/2 in three pipelines in the US

- Looking for partnering for the Asian market (China, Japan, South Korea)

Digital physician platform for over 2.5 million registered Chinese doctors. We also help US pharma, biotech and medical device companies strategize and promote products and services directly to Chinese physicians.